Overview

A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19

Status:
Not yet recruiting

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy of Favipiravir combined with supportive care for adult patients with COVID-19-Moderate type.

Phase:

Phase 3

Details

Lead Sponsor:

Zhejiang Hisun Pharmaceutical Co. Ltd.

Collaborator:

Opera CRO, a TIGERMED Group Company

Treatments:

Favipiravir